- Home
- TLX vs CSQ Comparison
TLX vs CSQ Comparison
Compare TLX & CSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLX
- CSQ
- Stock Information
- Founded
- TLX 2015
- CSQ 2003
- Country
- TLX Australia
- CSQ United States
- Employees
- TLX N/A
- CSQ N/A
- Industry
- TLX Biotechnology: Pharmaceutical Preparations
- CSQ Finance Companies
- Sector
- TLX Health Care
- CSQ Finance
- Exchange
- TLX Nasdaq
- CSQ Nasdaq
- Market Cap
- TLX 3.6B
- CSQ 3.1B
- IPO Year
- TLX N/A
- CSQ N/A
- Fundamental
- Price
- TLX $10.63
- CSQ $19.29
- Analyst Decision
- TLX Strong Buy
- CSQ
- Analyst Count
- TLX 4
- CSQ 0
- Target Price
- TLX $21.00
- CSQ N/A
- AVG Volume (30 Days)
- TLX 109.9K
- CSQ 220.3K
- Earning Date
- TLX 01-01-0001
- CSQ 01-01-0001
- Dividend Yield
- TLX N/A
- CSQ 7.53%
- EPS Growth
- TLX N/A
- CSQ N/A
- EPS
- TLX 0.04
- CSQ N/A
- Revenue
- TLX $664,225,558.00
- CSQ N/A
- Revenue This Year
- TLX N/A
- CSQ N/A
- Revenue Next Year
- TLX N/A
- CSQ N/A
- P/E Ratio
- TLX $333.76
- CSQ N/A
- Revenue Growth
- TLX 55.35
- CSQ N/A
- 52 Week Low
- TLX $8.93
- CSQ $12.50
- 52 Week High
- TLX $30.36
- CSQ $16.45
- Technical
- Relative Strength Index (RSI)
- TLX 52.01
- CSQ 56.36
- Support Level
- TLX $10.74
- CSQ $19.20
- Resistance Level
- TLX $11.00
- CSQ $19.47
- Average True Range (ATR)
- TLX 0.28
- CSQ 0.21
- MACD
- TLX 0.04
- CSQ 0.02
- Stochastic Oscillator
- TLX 63.77
- CSQ 74.29
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.